CompletedPhase 4

Daptomycin as Adjunctive Therapy for Staphylococcus Aureus Bacteremia

Canada102 participantsStarted 2016-12-01

Plain-language summary

The purpose of our study is to examine the effects of a second antibiotic, daptomycin, in combination with a beta lactam antibiotic on treating bloodstream infection caused by methicillin-susceptible S. aureus.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient has a methicillin susceptible Staphylococcus aureus bacteremia. Exclusion Criteria: * Underlying terminal illness * Significant contraindication to beta-lactam therapy (i.e. severe allergy, severe adverse drug reaction) * Expected death before 5 days * Microbiologically confirmed need for concomitant VANCOMYCIN or DAPTOMYCIN

What they're measuring

Blood culture clearance

Timeframe: 5 days

Trial details

NCT IDNCT02972983

SponsorMcGill University Health Centre/Research Institute of the McGill University Health Centre

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-07

View on ClinicalTrials.gov More Methicillin Susceptible Staphylococcus Aureus Septicemia trials